The eleven products that the European Medicines Agency’s key scientific committee, the CHMP, this week recommended for approval throughout Europe include five with orphan status and three generics. Of the 13 products the CHMP assessed for an opinion during its four-day meeting (Also see "EU CHMP Decides On New Oncology Drugs & New Treatments for Mastocytosis, Atopic Dermatitis" - Pink Sheet, 19 July, 2017.), two got the thumbs down. Eight products will have their current indications extended and one company has withdrawn the marketing application for one of its products.
The drugs that got positive opinions from the CHMP and that are now set for formal EU approval include the...






